Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 714 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07329257Recruiting
Project PENGUIN: Study of rare brain development disorders
This study looks at rare and ultra-rare conditions that affect brain development. It aims to learn more about what causes these conditions. You may join if you or your child have a diagnosed or suspected neurogenetic disorder.
Columbia, MissouriAges Up to 99 years - NCT07321015RecruitingPhase 2
Fluzoparib after platinum for advanced triple-negative breast cancer
This trial tests the PARP inhibitor fluzoparib as a maintenance treatment for women with advanced triple-negative breast cancer whose disease responded or stabilized after platinum-based chemotherapy. The goal is to see if taking fluzoparib daily can delay cancer growth.
TianjinAges 18–75 - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT07303465RecruitingPhase 2
Testing a new drug for KRAS G12D pancreatic cancer
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
NanjingAges 18–75 - NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT07304011RecruitingPhase 2
Olutasidenib and azacitidine for IDH1-mutated AML after venetoclax
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
Orange, CaliforniaAges 18 years+ - NCT07302321Recruiting
Needs of ALS patients with C9orf72 mutation and their caregivers
This study asks people with ALS who have a specific genetic change (C9orf72) and their caregivers to fill out an online survey. It aims to better understand their needs so that support can be improved.
Milan, LombardyAges 18 years+ - NCT07304739RecruitingPhase 2
Furmonertinib plus radiation and chemo for EGFR lung cancer with brain spread
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Cangzhou, HebeiAges 18–75 - NCT06878534Recruiting
Thyroid cancer genetic study for patients with follicular origin
This study looks at the genes and mutations in thyroid cancers that start in follicular cells. It aims to understand how these changes relate to how aggressive the cancer is.
NaplesAges 18 years+ - NCT07279402Recruiting
Real-world study of atezolizumab for advanced lung cancer
This trial looks at how well atezolizumab works for people with stage IV non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). It's for people getting atezolizumab as their first treatment.
AdanaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07282717Recruiting
Skin cell study for COL5A mutation and aortic aneurysm
This trial collects a small skin sample from adults with a COL5A gene mutation and thoracic aortic aneurysm. Researchers study the skin cells to better understand the condition and explore potential treatments.
San Donato Milanese, ItalyAges 18 years+ - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT06659458Recruiting
EGFR lung cancer gene study using advanced DNA sequencing
This trial uses long-read sequencing to study the EGFR gene in women with EGFR-positive lung cancer. It aims to learn more about the cancer's DNA to improve future treatments.
Baton Rouge, LouisianaAges 18–100 - NCT07270770RecruitingPhase 1
A New Drug BY002 for Relapsed Acute Leukemia with Genetic Changes
This phase 1 trial tests a new drug called BY002 for people with certain types of leukemia (AML, ALL, or MPAL) that have come back or not responded to treatment. It focuses on patients whose leukemia has a specific genetic change (KMT2A rearrangement or NPM1 mutation). The goal is to see if BY002 can help control the disease.
Suzhou, JiangsuAges 16 years+ - NCT07277361Recruiting
Quality of life study for Fabry disease patients aged 65+
This study looks at the quality of life of people aged 65 and older with Fabry disease. It includes patients who are receiving specific treatment and those who are not, to compare their experiences.
Paris, FranceAges 65 years+ - NCT07259590RecruitingPhase 1/Phase 2
GFH375 with cetuximab or chemo for KRAS G12D cancers
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07260175RecruitingPhase 2
Ivosidenib maintenance for IDH1-mutated bile duct cancer
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
AachenAges 18 years+ - NCT06291935RecruitingPhase 1
Gene therapy trial for retinitis pigmentosa with CNGA1 mutation
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
TübingenAges 18 years+ - NCT07252739RecruitingPhase 2
Study of pembrolizumab plus MK-1084 for KRAS G12C lung cancer
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
Clermont, FloridaAges 18 years+ - NCT07251673Recruiting
Study of Dravet syndrome in children with SCN1A gene changes
This study follows children with Dravet syndrome caused by a specific SCN1A gene change to understand how the condition develops over time. It may help families know more about what to expect.
Paris, Ap-hp / DRCIAges 6 months–21 years - NCT07249840RecruitingPhase 1
Testing ropeginterferon for high-risk JAK2 mutation carriers
This trial tests whether the drug ropeginterferon can help people with a JAK2 gene mutation who have additional risk factors but do not yet have a blood cancer. The goal is to see if treatment can prevent blood clots, high blood counts, or other complications.
Boston, MassachusettsAges 18 years+ - NCT07240766RecruitingPhase 2
New drug combo for KRAS G12D pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
Hangzhou, ZhejiangAges 18–75
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 714 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.